SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 15, 2016, Pages 2073-2084

  Ito, Hiroyuki ^a   Shinozaki, Masahiro ^a   Nishio, Shinya ^a   Abe, Mariko ^a  

^a 2 24 18 Higashikoiwa   (Japan)

Author keywords

canagliflozin; dapagliflozin; empagliflozin; ipragliflozin; Japanese; luseogliflozin; obesity; Sodium glucose cotransporter 2 inhibitors; tofogliflozin; weight reduction

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFOGLIFLOZIN; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

BODY WEIGHT; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; JAPANESE (PEOPLE); NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; JAPAN;

BODY WEIGHT; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; JAPAN; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84988956851     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2016.1232395     Document Type: Review

References (72)

1. S.E.Inzucchi, R.M.Bergenstal, J.B.Buse, et al. Management of hyperglycemia in type 2 diabetes, 2015:a patient-centered approach:update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
2. J.H.Wu, C.Foote, J.Blomster, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes:a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4:411–419.
3. A.Kashiwagi, K.Kazuta, Y.Takinami, et al. Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus:the BRIGHTEN study. Diabetology Int. 2015;6:8–18.
4. A.Kashiwagi, H.Kawano, K.Kazuta, et al. Long-term safety, tolerability and efficacy of ipragliflozin in Japanese patients with type 2 diabetes mellitus - IGNITE study. Japan Pharmacol Ther. 2015;43:85–100. Japanese, Abstract in English.
5. K.Kaku, A.Kiyosue, S.Inoue, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab. 2014;16:1102–1110.
6. K.Kaku, H.Maegawa, Y.Tanizawa, et al. Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes:an open-label study. Diabetes Ther. 2014;5:415–433.
7. Y.Seino, T.Sasaki, A.Fukatsu, et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus:a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin. 2014;30:1245–1255.
8. Y.Seino, K.Kaku, N.Inagaki, et al. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Endocr J. 2015;62:593–603.
9. K.Kaku, H.Watada, Y.Iwamoto, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus:a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65.
10. Y.Tanizawa, K.Kaku, E.Araki, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus:multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother. 2014;15:749–766.
11. N.Inagaki, K.Kondo, T.Yoshinari, et al. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise:a 24-week, randomized, double-blind, placebo-controlled, Phase III study. Expert Opin Pharmacother. 2014;15:1501–1515.
12. N.Inagaki, K.Kondo, T.Yoshinari, et al. Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes:a 52-week open-label study. J Diabetes Investig. 2015;6:210–218.
13. Drug information of empagliflozin. Japanese. [cited 2016 Aug25]. Available from:www.info.pmda.go.jp/go/interview/1/650168_396905XF1022_1_14Z_1F
14. T.Kadowaki, M.Haneda, N.Inagaki, et al. Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes:a randomized, double-blind, parallel-group study. Adv Ther. 2015;32:306–318.
15. Recommendation for the appropriate use of SGLT2 inhibitors. Japanese. (June 2014, revised May 2016). [cited 2016 Aug25]. Available from:http://www.fa.kyorin.co.jp/jds/uploads/recommendation_SGLT2.pdf
16. M.Abe, H.Ito, T.Omoto, et al. A case of diabetes mellitus complicated by cerebral infarction nine days after the initiation of a SGLT2 inhibitor. J Japan Diabetes Soc. 2014;57:843–847. Japanese, Abstract in English.
17. D.Suemaru, J.Maruyama, T.Ishizuka, et al. A case of diabetic ketoacidosis and acute myocardial infarction following the dapagliflozin administration for 4 days in an elderly diabetes patient. J Japan Diabetes Soc. 2016;59:435–442. Japanese, Abstract in English.
18. T.Hayami, Y.Kato, H.Kamiya, et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig. 2015;6:587–590.
19. B.Zinman, C.Wanner, J.M.Lachin, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.•• The first report demonstrating that T2DM patients at high risk for cardiovascular events who received empagliflozin had a lower rate of the primary composite cardiovascular outcome and of death from any cause.
20. Y.Ohkubo, H.Kishikawa, E.Araki, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus:a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–117.
21. M.Tominaga, H.Eguchi, H.Manaka, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920–924.
22. H.Sone, S.Tanaka, S.Tanaka, et al. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes:subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab. 2011;96:3448–3456.
23. The Organization for Economic Co-operation and Development (OECD). Obesity update. 2014; [cited 2016 Aug25]. Available from:http://www.oecd.org/health/Obesity-Update-2014.pdf
24. World Health Organization. Obesity and overweight. 2016; [cited 2016 Aug25]. Available from:http://www.who.int/mediacentre/factsheets/fs311/en/
25. Examination Committee of Criteria for ‘Obesity Disease’ in Japan. Japan society for the study of obesity. New criteria for ‘obesity disease’ in Japan. Circ J. 2002;66:987–992.
26. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. BMJ. 1998;317:703–713.
27. H.C.Gerstein, M.E.Miller, R.P.Byington, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559.
28. Ministry of Health, Labour and Welfare. 2015. Japanese. [cited 2016 Aug25]. Available from:http://www.mhlw.go.jp/file/04-Houdouhappyou-10904750-Kenkoukyoku-Gantaisakukenkouzoushinka/0000117311.pdf
29. Japan Diabetes Clinical Data Management Study Group. 2014. Japanese. [cited 2016 Aug25]. Available from:http://jddm.jp/data/index-2013.html
30. M.Tanaka, H.Ito, T.Omoto, et al. An analysis of the factors affecting the changes in medical expenses over the past 5 years in the management of out-patients with type 2 diabetes mellitus. J Japan Diabetes Soc. 2016;59:188–195. Japanese, Abstract in English.
31. Ministry of Health, Labour and Welfare. 2014. Japanese. [cited 2016 Aug25]. Available from:http://www.mhlw.go.jp/bunya/kenkou/eiyou/dl/h24-houkoku.pdf
32. M.A.Espeland, H.A.Glick, A.Bertoni, et al. Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes:the action for health in diabetes. Diabetes Care. 2014;37:2548–2556.
33. Astellas Pharma, Kotobuki Pharmaceutical and MSD. Result of a post-marketing surveillance of ipragliflozin. Japanese. [cited 2016 Aug25]. Available from:https://www.msdconnect.jp/static/mcijapan/images/eppv_suglat_201510.pdf
34. T.Kohro, T.Yamazaki, H.Sato, et al. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J. 2013;54:93–97.
35. S.Nishio, M.Abe, H.Ito Anagliptin in the treatment of type 2 diabetes:safety, efficacy, and patient acceptability. Diabetes Metab Syndr Obes. 2015;8:163–171.
36. T.Iizuka, K.Iemitsu, M.Takihata, et al. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes:interim outcome of the ASSIGN-K Study. J Clin Med Res. 2016;8:116–125.
37. K.Iemitsu, T.Iizuka, M.Takihata, et al. Factors influencing changes in hemoglobin A1c and body weight during treatment of type 2 diabetes with ipragliflozin:interim analysis of the ASSIGN-K study. J Clin Med Res. 2016;8:373–378.
38. Y.Terauchi, K.Yokote, I.Nakamura, et al. Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER):interim results of a post-marketing surveillance study. Expert Opin Pharmacother. 2016;17:463–471.• Study investigating the ADRs associated with ipragliflozin in elderly Japanese patients with T2DM.
39. E.Araki, Y.Onishi, M.Asano, et al. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes:results of the interim analysis of 16-week double-blind treatment period. J Diabetes Investig. 2016;7:555–564.
40. R.Nishimura, T.Osonoi, S.Kanada, et al. Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus:a randomized, double-blind, placebo-controlled, crossover study. Diabetes Obes Metab. 2015;17:800–804.
41. R.Nishimura, H.Omiya, K.Sugio, et al. Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet. Diabetes Obes Metab. 2016;18:702–706.
42. H.Jinnouchi, K.Nozaki, H.Watase, et al. Impact of reduced renal function on the glucose-lowering effects of luseogliflozin, a selective SGLT2 inhibitor, assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus. Adv Ther. 2016;33:460–479.
43. K.Utsunomiya, N.Shimmoto, M.Senda, et al. Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J-STEP/EL):a 12-week interim analysis. J Diabetes Investig. 2016;7:755–763.• Study investigating the ADRs associated with tofogliflozin in elderly Japanese patients with T2DM.
44. N.Inagaki, K.Kondo, T.Yoshinari, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes:a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013;15:1136–1145.
45. N.Inagaki, S.Harashima, N.Maruyama, et al. Efficacy and safety of canagliflozin in combination with insulin:a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2016;15:89.
46. B.Neal, V.Perkovic, D.de Zeeuw, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38:403–411.
47. The U.S. Food and Drug Administration. Dug safety communications. 2015; [cited2016 Aug25]. Available from:http://www.fda.gov/downloads/Drugs/DrugSafety/UCM461790.pdf
48. A.Tanaka, T.Inoue, M.Kitakaze, et al. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure:the CANDLE trial. Cardiovasc Diabetol. 2016;15:57.
49. E.Araki, Y.Tanizawa, Y.Tanaka, et al. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:665–674.
50. M.Shinozaki, S.Matsumoto, T.Omoto, et al. Clinical characteristics of the patients in whom the SGLT2 inhibitors were not successful in the treatment of type 2 diabetes. J Japan Diabetes Soc. 2016;59::S223. Japanese.
51. S.Shibata, H.Ito, A.Yamamoto, et al. Relationship between glycemic control evaluated using continuous glucose monitoring and carbohydrate intake in patients with gestational diabetes mellitus. J Japan Diabetes Soc. 2014;57:885–892. Japanese, Abstract in English.
52. H.Ito, T.Omoto, M.Abe, et al. Relationships between the duration of illness and the current status of diabetes in elderly patients with type 2 diabetes mellitus. Geriatr Gerontol Int. 2015 Dec 4. [Epub ahead of print].
53. E.Ferrannini, S.A.Veltkamp, R.A.Smulders, et al. Renal glucose handling:impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2013;36:1260–1265.
54. C.Wanner, S.E.Inzucchi, J.M.Lachin, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.•• Study demonstrating that T2DM patients at high risk for cardiovascular events who received empagliflozin were associated with slower progression of kidney disease and lower rates of clinically relevant renal events.
55. H.Ito, M.Mifune, E.Matsuyama, et al. Vildagliptin is effective for glycemic control in diabetic patients undergoing either hemodialysis or peritoneal dialysis. Diabetes Ther. 2013;4:321–329.
56. H.Ito, M.Abe, S.Antoku, et al. Comparison of the antidiabetic effects of linagliptin among groups with a normal renal function and a mild or severe renal impairment - retrospective observation study of Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2015;16:289–296.
57. P.H.Groop, M.E.Cooper, V.Perkovic, et al. Linagliptin lowers albuminuria ontop of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care. 2013; 36:3460–3468.
58. I.Masakane, S.Nakai, S.Ogata, et al. An overview of regular dialysis treatment in Japan (As of 31 December 2013). Ther Apher Dial. 2015;19:540–574.
59. H.Ito, Y.Takeuchi, H.Ishida, et al. High frequencies of diabetic micro- and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria. Nephrol Dial Transplant. 2010;25:1161–1167.
60. H.Ito, K.Oshikiri, M.Mifune, et al. The usefulness of the revised classification for chronic kidney disease by the KDIGO for determining the frequency of diabetic micro- and macroangiopathies in Japanese patients with type 2 diabetes mellitus. J Diabetes Complications. 2012;26:286–290.
61. H.Ito, S.Antoku, M.Furusho, et al. The prevalence of the risk factors for atherosclerosis among type 2 diabetic patients is greater in the progressive stages of chronic kidney disease. Nephron Extra. 2013;3:66–72.
62. The U.S. Food and Drug Administration, Drug safety communications, 2016. [cited2016 Aug25] http://www.fda.gov/downloads/Drugs/DrugSafety/UCM506772.pdf
63. M.Abdul-Ghani, S.Del Prato, R.Chilton, et al. SGLT2 inhibitors and cardiovascular risk:lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39:717–725.
64. N.Katsiki, N.Papanas, D.P.Mikhailidis. Dapagliflozin:more than just another oral glucose-lowering agent? Expert Opin Investig Drugs. 2010;19:1581–1589.
65. B.M.Scirica, D.L.Bhatt, E.Braunwald, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
66. W.B.White, C.P.Cannon, S.R.Heller, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
67. J.B.Green, M.A.Bethel, P.W.Armstrong, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
68. L.Li, S.Li, K.Deng, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes:systematic review and meta-analysis of randomised and observational studies. BMJ. 2016;352:i610.
69. H.Ito, Y.Komatsu, M.Mifune, et al. The estimated GFR, but not the stage of diabetic nephropathy graded by the urinary albumin excretion, is associated with the carotid intima-media thickness in patients with type 2 diabetes mellitus:a cross-sectional study. Cardiovasc Diabetol. 2010;9:18.
70. T.Mita, N.Katakami, H.Yoshii, et al. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes:the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care. 2016;39:139–148.
71. T.Mita, N.Katakami, T.Shiraiwa, et al. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes:the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE):a randomized controlled trial. Diabetes Care. 2016;39:455–464.
72. S.P.Marso, G.H.Daniels, K.Brown-Frandsen, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.